Search

Displaying results 2811 - 2820 of 10000 in total
  1. Drug

    Pork collagen

    go.drugbank.com/drugs/DB14100
    Approved

    It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden. … Pork Collagen is used within MACI® (autologous cultured chondrocytes on porcine collagen membrane) as an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic

  2. Target

    Proteasome subunit beta type-6

    go.drugbank.com/bio_entities/BE0003919
    TargetHumans

    Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. … This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex).

    Synonyms: Multicatalytic endopeptidase complex delta chain
  3. Drug

    Sitaxentan

    go.drugbank.com/drugs/DB06268
    ApprovedWithdrawn

    In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity. … Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008.

  4. Drug

    LS11

    go.drugbank.com/drugs/DB05918
    Investigational

    LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. … After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death.

  5. Drug

    Telaprevir

    go.drugbank.com/drugs/DB05521
    ApprovedWithdrawn

    Approved in May 2011 by the FDA, Incivek was indicated for the treatment of HCV genotype 1 in combination with [DB00811], [DB00008], and [DB00022] [FDA Label]. … Telaprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotype 1 [FDA Label].

    Synonyms: (1S,3aR,6aS)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamide
  6. Drug

    Black cohosh

    go.drugbank.com/drugs/DB13975
    Approved

    European settlers were said to use black cohosh as a tonic to support female reproductive health. … in treating the symptoms of sleep and mood disturbance, and hot flushes.

    Categories: Complex Mixtures
  7. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    On October 2021, Incyte Biosciences withdrew its application for a marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. … [L45603,L45613] The use of retifanlimab in combination with other oncology drugs for the treatment of metastatic gastroesophageal adenocarcinoma has also been evaluated.[A258383,A258388]

  8. Drug

    Pinaverium

    go.drugbank.com/drugs/DB09090
    ApprovedInvestigational

    Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. … It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function.

  9. Drug

    PEG-uricase

    go.drugbank.com/drugs/DB05321
    Investigational

    of severe, treatment-refractory gout in the United States in 2006. … PEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … Food and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc.